Acetyl-L-carnitine (carnicetine) in the treatment of early stages of Alzheimer’s disease and vascular dementia

Authors

Gavrilova, S. I., Kalyn, Ia B., Kolykhalov, I. V., Roshchina, I. F., Selezneva, N. D.

Journal

Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova / Ministerstvo Zdravookhraneniia I Meditsinskoĭ Promyshlennosti Rossiĭskoĭ Federatsii, Vserossiĭskoe Obshchestvo Nevrologov [I] Vserossiĭskoe Obshchestvo Psikhiatrov, Volume: 111, No.: 9, Pages.: 16-22

Year of Publication

2011

Abstract

Efficacy, safety and tolerability of acetyl-L-carnitine (ALC) were studied during the double-blind placebo-controlled 12-week trial in patients with mild (initial) dementia caused by the Alzheimer’s disease (AD) and vascular dementia (VD). ALC was administered in doses from 2250 to 3000 mg per day. Patient’s state was assessed with some scales (MMSE, CGI etc) and a battery of neuropsychological tests. The treatment effect of ALC was 2,8 times higher than in placebo-treated patients. The clinical improvement by CGI scores was significantly better in AD patients compared to VD and did not depend on the severity of baseline cognitive deficit. The drug was well-tolerated. Carnicetine can be recommended in the abovementioned doses for treatment of early stages of AD and VD.;

Keywords

acetylcarnitine, acetyllcarnitine, administration & dosage, aged, alc, alzheimer disease, dementia vascular, drug administration schedule, drug therapy, female, humans, male, middle aged, physiopathology, psychology, severity of illness index, treatment outcome, vitamin b complex

Types of Dementia

Alzheimer’s Disease, Vascular Dementia

Types of Study

Randomised Controlled Trial

Type of Outcomes

Cognition

Type of Interventions

Pharmaceutical Interventions

Herbal remedies, vitamins, dietary supplements